心筋炎の世界市場レポート 2025年

心筋炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.5％で20億7,000万米ドルに成長します。予測期間中の成長は、政府の支援や政策、標的治療の利用可能性、臨床試験の拡大、ヘルスケアインフラの改善、治療ガイドラインの進化などが要因となります。この期間の主な動向には、CRISPR-Cas9技術の進歩、3Dプリンティングの利用、AI主導の予測分析、バーチャルリアリティ（VR）技術、ウェアラブル心電図（ECG）デバイスの採用などがあります。

慢性疾患の有病率の上昇は、心筋炎市場の成長を促進すると予想されます。慢性疾患とは、1年以上続く長期的な健康状態のことで、多くの場合、継続的な医学管理、ライフスタイルの調整、治療が必要となります。慢性障害の発生が増加している背景には、人口の高齢化、座りがちなライフスタイル、食生活の乱れ、肥満率の上昇、環境汚染物質へのさらなる暴露などの要因があります。心筋に影響を及ぼす炎症性疾患である心筋炎は、心不全、不整脈、心筋症などの合併症を引き起こす可能性があるため、慢性的な健康問題の一因となります。例えば、2024年9月、英国を拠点とする心臓血管研究慈善団体British Heart Foundationが発表したデータによると、英国では約760万人が心臓・循環器疾患に罹患しています。このうち、約400万人が男性、約360万人が女性です。これらの疾患は英国における全死亡の約27％を占め、年間17万人以上の死亡につながり、これは1日当たり480人、3分に1人の死亡に相当します。その結果、慢性疾患の有病率の増加が心筋炎市場の成長に拍車をかけています。

心筋炎市場の主要企業は、治療の選択肢を広げ、患者の予後を改善するために、新薬の規制当局による承認を優先しています。薬事承認とは、医薬品、医療機器、または治療が一般に販売され、利用されることを許可する、政府または規制機関によって付与される正式な認可のことです。例えば、2022年5月、カナダを拠点とする製薬会社Cardiol Therapeutics Inc.は、再発性心膜炎に対するCardiolRxの多施設共同第II相非盲検パイロット試験について、FDAの治験薬（IND）承認を取得したと発表しました。この試験は、間もなく開始される急性心筋炎を対象とした同社の多国籍第II相試験と並行して実施される予定です。両試験とも、心血管系疾患に対する革新的な抗炎症療法の開発に焦点を当てています。さらに、CardiolRxは再発性心膜炎と急性心筋炎の両疾患で希少疾病用医薬品の指定を受けており、これらの疾患に対処できる可能性を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界心筋炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の心筋炎市場：成長率分析
• 世界の心筋炎市場の実績：規模と成長, 2019-2024
• 世界の心筋炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界心筋炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心筋炎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性心筋炎
• 慢性心筋炎
• リンパ性心筋炎
• 世界の心筋炎市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 手術
• その他の治療法
• 世界の心筋炎市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 画像検査
• 心臓カテーテル検査
• 心筋生検
• その他診断
• 世界の心筋炎市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の心筋炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の心筋炎市場急性心筋炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウイルス性心筋炎
• 細菌性心筋炎
• 真菌性心筋炎
• 世界の心筋炎市場慢性心筋炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己免疫性心筋炎
• 慢性活動性心筋炎
• 慢性炎症性心筋炎
• 世界の心筋炎市場リンパ性心筋炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性リンパ性心筋炎
• 薬剤誘発性リンパ性心筋炎
• ウイルス感染に伴うリンパ性心筋炎

第7章 地域別・国別分析

• 世界の心筋炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の心筋炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心筋炎市場：競合情勢
• 心筋炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• UCB S.A.
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Alnylam Pharmaceuticals Inc.
• Sobi（Swedish Orphan Biovitrum AB）
• BridgeBio Pharma Inc.
• Evotec SE
• Cardiol Therapeutics Inc.
• Cantargia AB

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心筋炎市場2029：新たな機会を提供する国
• 心筋炎市場2029：新たな機会を提供するセグメント
• 心筋炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myocarditis is a rare condition characterized by inflammation of the heart muscle, or myocardium. Treatment approaches focus on reducing inflammation, managing symptoms, and addressing underlying causes such as infections or autoimmune disorders.

The primary types of myocarditis include acute myocarditis, chronic myocarditis, and lymphocytic myocarditis. Acute myocarditis occurs when the heart muscle suddenly becomes inflamed, often due to a viral infection, leading to damage and impaired heart function. Treatment options consist of medications, surgery, and other interventions, while diagnostic methods include blood tests, imaging tests, cardiac catheterization, and heart muscle biopsy. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. Key end-users encompass hospitals, specialty clinics, home care services, and additional healthcare providers.

The myocarditis disease market research report is one of a series of new reports from The Business Research Company that provides myocarditis disease market statistics, including myocarditis disease industry global market size, regional shares, competitors with a myocarditis disease market share, detailed myocarditis disease market segments, market trends and opportunities, and any further data you may need to thrive in the myocarditis disease industry. This myocarditis disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myocarditis disease market size has grown strongly in recent years. It will grow from $1.50 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the rising prevalence of viral infections, greater awareness of autoimmune diseases, an increased incidence of cardiovascular diseases, advancements in treatment options for heart inflammation, and increased funding for cardiovascular research.

The myocarditis disease market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth during the forecast period can be driven by government support and policies, the availability of targeted therapies, the expansion of clinical trials, improved healthcare infrastructure, and evolving treatment guidelines. Key trends in this period include advancements in CRISPR-Cas9 technology, the use of 3D printing, AI-driven predictive analytics, virtual reality (VR) technologies, and the adoption of wearable electrocardiogram (ECG) devices.

The rising prevalence of chronic disorders is expected to drive the growth of the myocarditis disease market. Chronic disorders are long-term health conditions that persist for a year or more, often requiring continuous medical management, lifestyle adjustments, or treatment. The increasing occurrence of chronic disorders is attributed to factors such as aging populations, sedentary lifestyles, poor dietary habits, rising obesity rates, and greater exposure to environmental pollutants. Myocarditis, an inflammatory condition affecting the heart muscle, contributes to chronic health issues by potentially leading to complications such as heart failure, arrhythmias, and cardiomyopathy, which require long-term care and impact cardiovascular health. For instance, in September 2024, according to data published by the British Heart Foundation, a UK-based cardiovascular research charity, approximately 7.6 million people in the UK are affected by heart and circulatory diseases. Of these, around 4 million are males and 3.6 million are females. These conditions account for approximately 27% of all deaths in the UK, leading to over 170,000 deaths annually which is equivalent to 480 deaths per day or one death every three minutes. As a result, the increasing prevalence of chronic disorders is fueling the growth of the myocarditis disease market.

Leading companies in the myocarditis disease market are prioritizing regulatory approvals for new drugs to expand treatment options and improve patient outcomes. Regulatory approvals are formal authorizations granted by governmental or regulatory bodies, allowing drugs, medical devices, or treatments to be marketed and utilized by the public. For example, in May 2022, Cardiol Therapeutics Inc., a Canada-based pharmaceutical company, announced that it had received FDA Investigational New Drug (IND) authorization for a multicenter Phase II open-label pilot study of CardiolRx for recurrent pericarditis. This study will be conducted alongside the company's multinational Phase II trial for acute myocarditis, which is set to commence soon. Both studies focus on developing innovative anti-inflammatory therapies for cardiovascular diseases. Additionally, CardiolRx has been granted orphan drug designation for both recurrent pericarditis and acute myocarditis, underscoring its potential to address these conditions.

In May 2023, Kaiser Permanente, a US-based healthcare company, acquired Geisinger for $5 billion. This acquisition led to the establishment of Risant Health, a nonprofit health system dedicated to expanding value-based care. By integrating community-based health systems, Risant Health aims to improve healthcare accessibility and quality for diverse populations across the United States. Geisinger, a US-based healthcare provider, is actively involved in the management and treatment of myocarditis disease.

Major players in the myocarditis disease market are Pfizer Inc., Hoffmann-La Roche AG, Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Cipla Limited, Alnylam Pharmaceuticals Inc., Sobi (Swedish Orphan Biovitrum AB), BridgeBio Pharma Inc., Evotec SE, Cardiol Therapeutics Inc., and Cantargia AB.

North America was the largest region in the myocarditis disease market in 2024. The regions covered in myocarditis disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myocarditis disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myocarditis disease market consists of revenues earned by entities by providing services such as diagnosis and monitoring, pharmacological treatments, hospital care, lifestyle and rehabilitation services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The myocarditis disease market also includes sales of nonsteroidal anti-inflammatory drugs, corticosteroids, and beta-blockers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myocarditis Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myocarditis disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myocarditis disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myocarditis disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute Myocarditis; Chronic Myocarditis; Lymphocytic Myocarditis
• 2) By Treatment: Medication; Surgery; Other Treatments
• 3) By Diagnosis: Blood Tests; Imaging Tests; Cardiac Catheterization; Heart Muscle Biopsy; Others Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Acute Myocarditis: Viral Myocarditis; Bacterial Myocarditis; Fungal Myocarditis
• 2) By Chronic Myocarditis: Autoimmune Myocarditis; Chronic Active Myocarditis; Chronic Inflammatory Myocarditis
• 3) By Lymphocytic Myocarditis: Idiopathic Lymphocytic Myocarditis; Drug-Induced Lymphocytic Myocarditis; Lymphocytic Myocarditis Associated with Viral Infections
• Companies Mentioned: Pfizer Inc.; Hoffmann-La Roche AG; Merck & Co Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myocarditis Disease Market Characteristics

3. Myocarditis Disease Market Trends And Strategies

4. Myocarditis Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Myocarditis Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myocarditis Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myocarditis Disease Market Growth Rate Analysis
• 5.4. Global Myocarditis Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myocarditis Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myocarditis Disease Total Addressable Market (TAM)

6. Myocarditis Disease Market Segmentation

• 6.1. Global Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Myocarditis
• Chronic Myocarditis
• Lymphocytic Myocarditis
• 6.2. Global Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.3. Global Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Imaging Tests
• Cardiac Catheterization
• Heart Muscle Biopsy
• Others Diagnosis
• 6.4. Global Myocarditis Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Myocarditis Disease Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Myocarditis Disease Market, Sub-Segmentation Of Acute Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Myocarditis
• Bacterial Myocarditis
• Fungal Myocarditis
• 6.7. Global Myocarditis Disease Market, Sub-Segmentation Of Chronic Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune Myocarditis
• Chronic Active Myocarditis
• Chronic Inflammatory Myocarditis
• 6.8. Global Myocarditis Disease Market, Sub-Segmentation Of Lymphocytic Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Lymphocytic Myocarditis
• Drug-Induced Lymphocytic Myocarditis
• Lymphocytic Myocarditis Associated with Viral Infections

7. Myocarditis Disease Market Regional And Country Analysis

• 7.1. Global Myocarditis Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myocarditis Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myocarditis Disease Market

• 8.1. Asia-Pacific Myocarditis Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myocarditis Disease Market

• 9.1. China Myocarditis Disease Market Overview
• 9.2. China Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myocarditis Disease Market

• 10.1. India Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myocarditis Disease Market

• 11.1. Japan Myocarditis Disease Market Overview
• 11.2. Japan Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myocarditis Disease Market

• 12.1. Australia Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myocarditis Disease Market

• 13.1. Indonesia Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myocarditis Disease Market

• 14.1. South Korea Myocarditis Disease Market Overview
• 14.2. South Korea Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myocarditis Disease Market

• 15.1. Western Europe Myocarditis Disease Market Overview
• 15.2. Western Europe Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myocarditis Disease Market

• 16.1. UK Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myocarditis Disease Market

• 17.1. Germany Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myocarditis Disease Market

• 18.1. France Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myocarditis Disease Market

• 19.1. Italy Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myocarditis Disease Market

• 20.1. Spain Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myocarditis Disease Market

• 21.1. Eastern Europe Myocarditis Disease Market Overview
• 21.2. Eastern Europe Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myocarditis Disease Market

• 22.1. Russia Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myocarditis Disease Market

• 23.1. North America Myocarditis Disease Market Overview
• 23.2. North America Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myocarditis Disease Market

• 24.1. USA Myocarditis Disease Market Overview
• 24.2. USA Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myocarditis Disease Market

• 25.1. Canada Myocarditis Disease Market Overview
• 25.2. Canada Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myocarditis Disease Market

• 26.1. South America Myocarditis Disease Market Overview
• 26.2. South America Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myocarditis Disease Market

• 27.1. Brazil Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myocarditis Disease Market

• 28.1. Middle East Myocarditis Disease Market Overview
• 28.2. Middle East Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myocarditis Disease Market

• 29.1. Africa Myocarditis Disease Market Overview
• 29.2. Africa Myocarditis Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myocarditis Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myocarditis Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myocarditis Disease Market Competitive Landscape And Company Profiles

• 30.1. Myocarditis Disease Market Competitive Landscape
• 30.2. Myocarditis Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Myocarditis Disease Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Gilead Sciences Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. UCB S.A.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Cipla Limited
• 31.10. Alnylam Pharmaceuticals Inc.
• 31.11. Sobi (Swedish Orphan Biovitrum AB)
• 31.12. BridgeBio Pharma Inc.
• 31.13. Evotec SE
• 31.14. Cardiol Therapeutics Inc.
• 31.15. Cantargia AB

32. Global Myocarditis Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myocarditis Disease Market

34. Recent Developments In The Myocarditis Disease Market

35. Myocarditis Disease Market High Potential Countries, Segments and Strategies

• 35.1 Myocarditis Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myocarditis Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myocarditis Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer